Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $220.00 Consensus Target Price from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $220.00.

KRYS has been the topic of several recent research reports. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter valued at approximately $40,000. Huntington National Bank increased its position in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $95,000. KBC Group NV increased its position in shares of Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after acquiring an additional 132 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $189.18 on Monday. Krystal Biotech has a one year low of $141.72 and a one year high of $219.34. The stock’s 50-day moving average is $165.34 and its 200 day moving average is $173.69. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of 63.27 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 earnings per share. On average, sell-side analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).